Significant Surge in DARZALEX Sales
In a recent update, Genmab A/S (NASDAQ: GMAB) announced impressive first-quarter sales figures for their flagship product, DARZALEX (daratumumab). They reported that global net sales reached a remarkable USD 3,237 million during this period, highlighting the increasing adoption and demand for this innovative therapy.
Understanding the Revenue Breakdown
Based on reports by Johnson & Johnson (J&J), the breakdown of DARZALEX sales shows that the U.S. market accounted for approximately USD 1,829 million, while sales from the rest of the world contributed USD 1,409 million. Genmab benefits from royalties on these sales, solidifying its financial health and showcasing the collaborative synergy with J&J under their exclusive license agreement.
About DARZALEX and Its Developments
DARZALEX is a monoclonal antibody that targets CD38, a protein expressed on the surface of multiple myeloma cells. Its efficacy has made it a cornerstone in treating various hematological malignancies. The recent sales figures reflect a growing acceptance and trust in this therapy from healthcare providers and patients alike.
Additionally, Genmab continues to enhance its product offerings with the subcutaneous formulation of daratumumab, branded as DARZALEX FASPRO in the United States. This innovative delivery method has improved convenience and accessibility for patients, contributing to its robust sales performance.
Genmab's Vision for the Future
Founded over 25 years ago, Genmab aims to revolutionize the treatment landscape for oncology and other challenging diseases through groundbreaking antibody technologies. Their vision is to develop next-generation antibody medicines that will have a profound impact on patient lives by 2030. The company is committed to pushing the boundaries of science and innovation.
With a strong presence in regions including North America, Europe, and Asia-Pacific, Genmab is well-positioned to continue expanding its reach in the biopharmaceutical market. The dedication of their experienced and passionate team fuels their ongoing success in antibody therapeutics.
Contact Information for Genmab
Genmab encourages those interested in learning more about their developments or about DARZALEX to reach out directly:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What are the key figures for DARZALEX sales in Q1 2025?
Genmab reported global net sales of DARZALEX at USD 3,237 million, with USD 1,829 million from the U.S. market.
What is the significance of the partnership with J&J?
The partnership allows Genmab to receive royalties on worldwide net sales of DARZALEX, solidifying its financial future while expanding patient access to the medication.
What does DARZALEX treat?
DARZALEX is primarily used for treating multiple myeloma and has shown effectiveness in various hematological malignancies.
What strategies is Genmab using to improve patient lives?
Genmab focuses on developing innovative antibody therapies and plans to enhance its pipeline with next-generation medicines by 2030.
How can patients and healthcare providers connect with Genmab?
Interested individuals can contact Genmab via email or by phone, with available contacts for both communications and investor relations.
